#00365
People worldwide face bacterial infections that no longer respond to available antibiotics, increasing treatment failure, severe illness, deaths and the risks of routine medical care.
Scientific risk, weak commercial returns and unequal market access leave too few innovative antibiotics for priority resistant pathogens and limit delivery after approval.
Patients receive antibiotics when not needed, or receive unnecessarily broad, long, or poorly selected treatment, increasing avoidable selection pressure and adverse effects.
Countries lack complete, comparable, and sustainably financed systems connecting antibiotic use, resistance, policy, and outcomes across human, animal, and environmental health.
Waste from pharmaceutical manufacturing, healthcare, households, farms and sewage systems releases antibiotics, resistant bacteria and resistance genes into environmental reservoirs.
Routine and poorly controlled antimicrobial use in livestock and aquaculture selects resistant bacteria that can spread through animals, food, workers, waste and the environment.
Patients and communities are exposed to resistant bacteria through preventable transmission, particularly where infection prevention, sanitation, isolation, and outbreak coordination are weak.
Many patients, especially in resource-limited settings, cannot obtain timely microbiology, susceptibility testing, or the effective antibiotics needed to treat resistant infections.